` Comparison: AZTA vs 207940 - Alpha Spread

AZTA
vs
207940

Over the past 12 months, AZTA has underperformed Samsung Biologics Co Ltd, delivering a return of -36% compared to the Samsung Biologics Co Ltd's 0% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
AZTA
207940
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

AZTA Intrinsic Value
34.11 USD
Undervaluation 18%
Intrinsic Value
Price
Intrinsic Value
512 684.3594 KRW
Overvaluation 49%
Intrinsic Value
Price
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
Azenta Inc
NASDAQ:AZTA
27.88 USD
Samsung Biologics Co Ltd
KRX:207940
999 999.9999 KRW
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
AZTA, 207940

AZTA
207940
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Azenta Inc
Revenue
Samsung Biologics Co Ltd
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
AZTA, 207940

AZTA
207940
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Azenta Inc
NASDAQ:AZTA
Samsung Biologics Co Ltd
KRX:207940
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

AZTA
44.6%
Samsung Biologics Co Ltd
56.3%

Operating Margin

AZTA
-2.8%
Samsung Biologics Co Ltd
36.6%

Net Margin

AZTA
-9.7%
Samsung Biologics Co Ltd
29%

FCF Margin

AZTA
5.2%
Samsung Biologics Co Ltd
13.1%

ROE

AZTA
-3.4%
Samsung Biologics Co Ltd
14%

ROA

AZTA
-2.8%
Samsung Biologics Co Ltd
9.3%

ROIC

AZTA
9.1%
Samsung Biologics Co Ltd
10.1%

ROCE

AZTA
-0.9%
Samsung Biologics Co Ltd
14.9%

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
AZTA, 207940

Loading
AZTA
207940
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
AZTA, 207940

Loading
AZTA
207940
Difference
www.alphaspread.com

Performance By Year
AZTA, 207940

Loading
AZTA
207940
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare AZTA to other stocks
0KHE
PerkinElmer Inc
P
More expensive
vs AZTA
TMO
Thermo Fisher Scientific...
More expensive
vs AZTA
DHR
Danaher Corp
More expensive
vs AZTA
LONN
Lonza Group AG
More expensive
vs AZTA
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett